Top

Published in:

Open Access 01-12-2013 | Primary research

A specific miRNA signature promotes radioresistance of human cervical cancer cells

Authors: Bin Zhang, Jun Chen, Zhenghua Ren, Yongbin Chen, Jinhui Li, Xia Miao, Yang Song, Tao Zhao, Yurong Li, Yongquan Shi, Dongqing Ren, Junye Liu

Published in: Cancer Cell International | Issue 1/2013

Abstract

Background

The mechanisms responsible for cervical cancer radioresistance are still largely unexplored. The present study aimed to identify miRNAs associated with radioresistance of cervical cancer cells.

Methods

The radioresistant cervical cancer cell variants were established by repeated selection with irradiation. The miRNA profiles of radioresistant cells and their corresponding controls were analyzed and compared using microarray. Differentially expressed miRNAs were confirmed by quantitative real-time PCR. Cervical cancer cells were transfected with miRNA-specific mimics or inhibitors. Radiosensitivity of cervical cancer cells were determined using colony-forming assay.

Results

Among the differentially expressed miRNAs, 20 miRNAs showed the similar pattern of alteration (14 miRNAs were overexpressed whilst 6 were suppressed) in all three radioresistant cervical cancer cell variants compared to their controls. A miRNA signature consisting of 4 miRNAs (miR-630, miR-1246, miR-1290 and miR-3138) exhibited more than 5 folds of increase in radioresistant cells. Subsequent analysis revealed that these four miRNAs could be up-regulated in cervical cancer cells by radiation treatment in both time-dependent and dose-dependent manners. Ectopic expression of each of these 4 miRNAs can dramatically increase the survival fraction of irradiated cervical cancer cells. Moreover, inhibition of miR-630, one miRNA of the specific signature, could reverse radioresistance of cervical cancer cells.

Conclusions

The present study indicated that miRNA is involved in radioresistance of human cervical cancer cells and that a specific miRNA signature consisting of miR-630, miR-1246, miR-1290 and miR-3138 could promote radioresistance of cervical cancer cells.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008, 2010 (127): 2893-2917.

Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD, Bae DS: Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer. 2005, 117: 194-201. 10.1002/ijc.21180.CrossRefPubMed

Huang EY, Wang CJ, Chen HC, Fang FM, Huang YJ, Wang CY, Hsu HC: Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys. 2008, 72: 834-842. 10.1016/j.ijrobp.2008.01.035.CrossRefPubMed

Parliament MB, Murray D: Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol. 2010, 20: 232-240. 10.1016/j.semradonc.2010.05.003.CrossRefPubMed

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56: 4509-4515.PubMed

Rofstad EK, Sundfør K, Lyng H, Tropé CG: Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2000, 83: 354-359. 10.1054/bjoc.2000.1266.PubMedCentralCrossRefPubMed

Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A, Friese K: Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet. 2011, 283: 109-113. 10.1007/s00404-010-1389-1.CrossRefPubMed

Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, Weber B, Guillemet C, Paraiso D, Pujade-Lauraine E: Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol. 2009, 113: 16-20. 10.1016/j.ygyno.2008.12.040.CrossRefPubMed

Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K: Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys. 2007, 69: 111-117. 10.1016/j.ijrobp.2007.02.050.CrossRefPubMed

10.

Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, Pintilie M, Levin W, Manchul L, Fyles A: A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007, 67: 97-103. 10.1016/j.ijrobp.2006.08.024.CrossRefPubMed

11.

Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, Kim BG, Lee JH, Bae DS: Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006, 94: 1678-1682.PubMedCentralPubMed

12.

Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK: Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005, 99: 415-421. 10.1016/j.ygyno.2005.05.045.CrossRefPubMed

13.

Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 2008, 455: 58-63. 10.1038/nature07228.CrossRefPubMed

14.

Chi SW, Zang JB, Mele A, Darnell RB: Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009, 460: 479-486.PubMedCentralPubMed

15.

Krützfeldt J, Poy MN, Stoffel M: Strategies to determine the biological function of microRNAs. Nat Genet. 2006, 38: S14-S19. 10.1038/ng1799.CrossRefPubMed

16.

Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.CrossRefPubMed

17.

Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 2009, 136: 586-591. 10.1016/j.cell.2009.02.005.PubMedCentralCrossRefPubMed

18.

Yang W, Sun T, Cao J, Liu F, Tian Y, Zhu W: Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012, 318: 944-954. 10.1016/j.yexcr.2012.02.010.CrossRefPubMed

19.

Jiang P, Rao EY, Meng N, Zhao Y, Wang JJ: MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol. 2010, 5: 100-10.1186/1748-717X-5-100.PubMedCentralCrossRefPubMed

20.

Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG: MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl). 2012, 90: 1449-1458. 10.1007/s00109-012-0924-x.CrossRef

21.

Zhang CZ, Han L, Zhang AL, Fu YC, Yue X, Wang GX, Jia ZF, Pu PY, Zhang QY, Kang CS: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010, 10: 367-10.1186/1471-2407-10-367.CrossRef

22.

Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G: HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res. 2010, 316: 1985-1993. 10.1016/j.yexcr.2010.02.028.CrossRefPubMed

23.

Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Shozu M, Seki N: Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol. 2013, 42: 1523-1532.PubMedCentralPubMed

24.

Li J, Ping Z, Ning H: MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012, 13: 16053-16064. 10.3390/ijms131216053.PubMedCentralCrossRefPubMed

25.

Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O’Sullivan B, Liu FF: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011, 71: 2381-2391. 10.1158/0008-5472.CAN-10-2754.CrossRefPubMed

26.

Zhang Y, Dai Y, Huang Y, Ma L, Yin Y, Tang M, Hu C: Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. J Obstet Gynaecol Res. 2009, 35: 842-849. 10.1111/j.1447-0756.2009.01055.x.CrossRefPubMed

27.

Ma D, Zhang YY, Guo YL, Li ZJ, Geng L: Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin Med J (Engl). 2012, 125: 4270-4276.

28.

Rao Q, Shen Q, Zhou H, Peng Y, Li J, Lin Z: Aberrant microRNA expression in human cervical carcinomas. Med Oncol. 2012, 29: 1242-1248. 10.1007/s12032-011-9830-2.CrossRefPubMed

29.

Dunn W, DuRaine G, Reddi AH: Profiling microRNA expression in bovine articular cartilage and implications for mechanotransduction. Arthritis Rheum. 2009, 60: 2333-2339. 10.1002/art.24678.CrossRefPubMed

30.

Chaudhry MA, Omaruddin RA, Brumbaugh CD, Tariq MA, Pourmand N: Identification of radiation-induced microRNA transcriptome by next-generation massively parallel sequencing. J Radiat Res. 2013, 54: 808-822. 10.1093/jrr/rrt014.PubMedCentralCrossRefPubMed

31.

Chaudhry MA, Sachdeva H, Omaruddin RA: Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol. 2010, 29: 553-561. 10.1089/dna.2009.0978.CrossRefPubMed

32.

Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G: miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70: 1793-1803. 10.1158/0008-5472.CAN-09-3112.CrossRefPubMed

33.

Huang Y, Guerrero-Preston R, Ratovitski EA: Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle. 2012, 11: 1247-1259. 10.4161/cc.11.6.19670.PubMedCentralCrossRefPubMed

34.

Bach D, Fuereder J, Karbiener M, Scheideler M, Ress AL, Neureiter D, Kemmerling R, Dietze O, Wiederstein M, Berr F, Plaetzer K, Kiesslich T, Pichler M: Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B. 2013, 120C: 74-81.CrossRef

35.

Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, Akanuma N, Komatsu A, Jitsukawa M, Matsubara H: Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013, 108: 644-652. 10.1038/bjc.2013.8.PubMedCentralCrossRefPubMed

36.

Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, Chevassut TJ, Newbury SF: Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012, 107: 1987-1996. 10.1038/bjc.2012.525.PubMedCentralCrossRefPubMed

37.

Wu J, Ji X, Zhu L, Jiang Q, Wen Z, Xu S, Shao W, Cai J, Du Q, Zhu Y, Mao J: Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Lett. 2013, 329: 155-163. 10.1016/j.canlet.2012.10.038.CrossRefPubMed

38.

Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, Muckenthaler MU: A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006, 12: 913-920. 10.1261/rna.2332406.PubMedCentralCrossRefPubMed

Title: A specific miRNA signature promotes radioresistance of human cervical cancer cells
Authors: Bin Zhang
Jun Chen
Zhenghua Ren
Yongbin Chen
Jinhui Li
Xia Miao
Yang Song
Tao Zhao
Yurong Li
Yongquan Shi
Dongqing Ren
Junye Liu
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/1475-2867-13-118

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN

Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model

Spindle and kinetochore associated complex subunit 1 regulates the proliferation of oral adenosquamous carcinoma CAL-27 cells in vitro

Antiproliferative activity and apoptosis-inducing mechanism of constituents from Toona sinensis on human cancer cells

The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies

Beclin1 inhibition promotes autophagy and decreases gemcitabine–induced apoptosis in Miapaca2 pancreatic cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer